Table 4.

Estimated Margin Means of Fasting Serum-Free Fatty Acids Changes and Pairwise Comparison in Percentage of Free Fatty Acids

Treated Group	Triglyceride (168.7)	Total Cholesterol (185.8)	High-Density Lipoprotein (40.3)	Non-high Density Lipoprotein (145.5)	Triglyceride-Glucose Index
Placebo	105.05 ± 3.164	105.08 ± 3.158	105.29 ± 3.185	105.17 ± 3.157	105.06 ± 3.140
Orlistat	82.28 ± 3.163	82.35 ± 3.163	82.21 ± 3.159	82.37 ± 3.156	82.27 ± 3.140
Telmisartan	95.98 ± 3.28	95.88 ± 3.229	95.81 ± 3.237	95.77 ± 3.234	95.98 ± 3.205
Placebo versus orlistat ( P -value)	<.001	<.001	<.001	<.001	<.001
Placebo versus telmisartan ( P -value)	.146	.137	.125	.125	.140
Orlistat versus telmisartan ( P -value)	.010	.012	.011	.013	.110

Analysis of covariance test was used for adjusting each variable of lipid profile.